kyoto.jpeg

kyoto

kyotovisitorshost.jpeg

kyotovisitorshost

General information

Announcements(0)

Overview

Pre-registration

Abstract Submission (Oral/Poster Presentation)

Guidelines for Writing Abstracts (Oral/Poster Pres

Program

Sessions

Search presentations

pharm140_e.png

icon_20251203154432448.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

A password that applicants have been notified of is required to view abstracts.<br>If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.<br>We will reply after confirming that you were a participant.<br>Thank you for your understanding.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Profile management

Announcements

Bookmark

Download PDF for print

Timetable

Development of the inhibitors for HIV-1 reverse transcriptase RNase H activity

Recent research & development (R&D) based on novel concepts and multidisciplinary pharmaceutical information have brought new effective therapeutic drugs for virus infection. For example, the mechanistic concept of new anti-HIV integrase inhibitors, which has greatly improved the prognosis of HIV-infected people, was applied to development of the new anti-influenza virus drug as a "chelate" drug. Thus, there has been a great focus on multidisciplinary R&D beyond a virus target, utilizing such novel mechanistic concepts. Here, in this session, five scientists present their unique studies on novel antiviral drugs of which the concepts are highly applicable across the fields: 1) a new strategy against membrane fusion upon HIV infection, 2) anti-influenza virus drug, Baloxavir, 3) anti-HIV RNaseH inhibitor, 4) new compound targets against Kaposi's sarcoma-associated herpesvirus infection, 5) latency-reversing agents for a new HIV-cure approach. With maximized utilization of their unique concepts, the presentations will aid us for further development of novel therapeutic drugs for virus infection as well as other diseases that is not related to virus infection.

Research frontiers on viral infection and antiviral therapy -drug discovery and development based on new concepts-

The 140th Annual Meeting of the Pharmaceutical Society of Japan (Kyoto)

Presentation Information

[S15-2]Development of the inhibitors for HIV-1 reverse transcriptase RNase H activity

Password required to view